Pages that link to "Q35142268"

The following pages link to Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. (Q35142268):

Displaying 19 items.

• A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K (Q30301096) (← links)
• Histone/protein deacetylase SIRT1 is an anticancer therapeutic target (Q33785586) (← links)
• Melanoma: clinical features and genomic insights. (Q34083191) (← links)
• Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide (Q34488011) (← links)
• Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma (Q34497045) (← links)
• Therapeutic interventions to disrupt the protein synthetic machinery in melanoma (Q36473355) (← links)
• Signet-ring cell melanoma with sentinel lymph node metastasis: A case report with immunohistochemical analysis and review of the clinicopathological features (Q37388633) (← links)
• Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma (Q37561380) (← links)
• BRAF and beyond: Tailoring strategies for the individual melanoma patient (Q37702515) (← links)
• Obesity and melanoma: exploring molecular links (Q38095892) (← links)
• Melanoma: Advances in Targeted Therapy and Molecular Markers (Q38557217) (← links)
• Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer (Q38631833) (← links)
• Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1. (Q38830266) (← links)
• Analysis of TSC1 mutation spectrum in mucosal melanoma (Q47353674) (← links)
• Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases. (Q47612204) (← links)
• Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance). (Q52582137) (← links)
• PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro. (Q54113534) (← links)
• Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL-24 enhances the antitumor effect of temozolomide against melanoma (Q58577417) (← links)
• Systemic Therapy in Metastatic Melanoma. (Q64892250) (← links)